Novartis updates pediatric asciminib CML trial; opens new schizophrenia drug studyNov 13Weekly roundup, 6 itemsasciminibinotuzumab ozogamicin
The company: FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemNov 10Regulatory decisionasciminibNovartisRecord notice
Novartis updates Scemblix label; registers PV real-world study and CAD trialSep 24Weekly roundup, 3 itemsasciminibNovartis
Enliven reports Phase 1 CML data for ELVN-001, aligns with FDA on Phase 3 designAug 5Quarterly updateEnliven Therapeutics
Novartis: Mayzent label update approved; four real-world studies registered or recruitingJul 2Weekly roundup, 7 itemsalpelisibFludarabine